NSE · CORONA · Pharmaceuticals
Corona Remedies Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹422 Cr with net profit ₹60 Cr — a 14.23% net margin, versus 13.09% the period before.
Shareholding
As of 2026-06-30
- Promoter69%
- Public14.48%
- FII3.63%
- DII12.9%
20,185 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.7× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #26 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.35 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.74 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.69 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.49 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Corona Remedies Limited(this company) | ₹13,460 Cr | 63.42 | 18.02 | 24.79% | 13.46% |
AI analysis
AI-generated · google/gemini-2.5-flashCorona Remedies Limited (CORONA) is listed with a market capitalization of Rs 12514 Cr. The company reported revenue of Rs 1413.83 Cr and a profit margin of 13.19%. Its earnings per share (EPS) stood at 32.68.
Positives
- +Revenue grew by 17.9%.
- +Return on equity (ROE) is 24.79%.
- +Return on capital employed (ROCE) is 27.13%.
- +The debt-to-equity ratio is low at 0.19.
- +Promoter holding of 68.9959% is stable and no shares are pledged.
Negatives
- −The trailing twelve months PE Ratio is elevated at 276.13.
- −Dividend yield is 49%, which can indicate dividend out of proportion to earnings, or that the dividend yield is presented incorrectly.
- −Net profit in Dec 2025 was Rs 41.27 Cr, lower than Rs 52.32 Cr in Sept 2025.
- −The latest available annual EPS (Mar 2026) is Rs 30.27, which is lower than the TTM EPS of Rs 32.68 due to fluctuations in quarterly performance.
- −The number of shareholders has significantly decreased from 31035 in Dec 2025 to 20185 in Jun 2026.
Financial performance
Corona Remedies Limited recorded a revenue of Rs 1413.83 Cr in Mar 2026, demonstrating a revenue growth of 17.9%. The net profit for the same period was Rs 185.12 Cr. Quarterly revenue has fluctuated, with Rs 346.54 Cr in Jun 2025, Rs 361.13 Cr in Sept 2025, Rs 342.42 Cr in Dec 2025, and Rs 353.09 Cr in Mar 2026.
Profitability & returns
The company’s profit margin was 13.19%. Return on equity (ROE) was 24.79%, and return on capital employed (ROCE) was 27.13%. Earnings per share (EPS) for the latest available annual period (Mar 2026) was 30.27, while the TTM EPS is 32.68.
Balance sheet
Corona Remedies Limited has a debt-to-equity ratio of 0.19, indicating a low level of debt relative to equity. The book value per share is Rs 122.12.
Ownership & pledges
As of June 30, 2026, promoters held 68.9959% of the company's shares. Public shareholding was 14.476%, while DIIs held 12.8994% and FIIs held 3.6287%. The total institutional holding was 16.5281%. There were no promoter shares pledged.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.